| Literature DB >> 31266770 |
Mautin Hundeyin1, Emma Kurz1, Ankita Mishra1, Juan Andres Kochen Rossi1, Shannon M Liudahl2, Kenna R Leis2, Harshita Mehrotra1, Mirhee Kim1, Luisana E Torres1, Adesola Ogunsakin1, Jason Link3,4, Rosalie C Sears3,4,5, Shamilene Sivagnanam6, Jeremy Goecks5,6, K M Sadeq Islam1, Igor Dolgalev7, Shivraj Savadkar1, Wei Wang1, Berk Aykut1, Joshua Leinwand1, Brian Diskin1, Salma Adam1, Muhammad Israr1, Maeliss Gelas1, Justin Lish1, Kathryn Chin1, Mohammad Saad Farooq1, Benjamin Wadowski1, Jingjing Wu1, Suhagi Shah8, Dennis O Adeegbe8, Smruti Pushalkar9, Varshini Vasudevaraja7, Deepak Saxena9, Kwok-Kin Wong8, Lisa M Coussens2,4,5, George Miller10,11.
Abstract
Unconventional T-lymphocyte populations are emerging as important regulators of tumor immunity. Despite this, the role of TCRαβ+CD4-CD8-NK1.1- innate αβ T cells (iαβT) in pancreatic ductal adenocarcinoma (PDA) has not been explored. We found that iαβTs represent ∼10% of T lymphocytes infiltrating PDA in mice and humans. Intratumoral iαβTs express a distinct T-cell receptor repertoire and profoundly immunogenic phenotype compared with their peripheral counterparts and conventional lymphocytes. iαβTs comprised ∼75% of the total intratumoral IL17+ cells. Moreover, iαβT-cell adoptive transfer is protective in both murine models of PDA and human organotypic systems. We show that iαβT cells induce a CCR5-dependent immunogenic macrophage reprogramming, thereby enabling marked CD4+ and CD8+ T-cell expansion/activation and tumor protection. Collectively, iαβTs govern fundamental intratumoral cross-talk between innate and adaptive immune populations and are attractive therapeutic targets. SIGNIFICANCE: We found that iαβTs are a profoundly activated T-cell subset in PDA that slow tumor growth in murine and human models of disease. iαβTs induce a CCR5-dependent immunogenic tumor-associated macrophage program, T-cell activation and expansion, and should be considered as novel targets for immunotherapy.See related commentary by Banerjee et al., p. 1164.This article is highlighted in the In This Issue feature, p. 1143. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31266770 PMCID: PMC6726581 DOI: 10.1158/2159-8290.CD-19-0161
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397